Clinical Trials Browser

INDUSTRY × trastuzumab deruxtecan × Gastrointestinal × Clear all

Astrocytoma, Breast Neoplasms, Fallopian Tube Neoplasms, Glioma, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms

NCT07124000 2026-06-01

DP-04

Recruiting

100 enrolled

DermatologicGastrointestinalGenitourinaryGynecologicHead & NeckSarcomaThoracic

Adenocarcinoma, Anus Neoplasms, Urinary Bladder Neoplasms, Carcinoma, Renal Cell, Uterine Cervical Neoplasms, Esophageal Neoplasms, Gallbladder Neoplasms, Gastrointestinal Neoplasms, Head and Neck Neoplasms, Liver Neoplasms, Melanoma, Mouth Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Salivary Gland Neoplasms, Sarcoma, Testicular Neoplasms, Thyroid Neoplasms, Urethral Neoplasms, Vaginal Neoplasms, Vulvar Neoplasms, Endometrial Neoplasms, Gastrointestinal Stromal Tumors, Small Cell Lung Carcinoma

NCT04704934 2026-05-27

Trastuzumab Deruxtecan for Subjects With HER2-Positive Gastric Cancer or Gastro-Esophageal Junction Adenocarcinoma After Progression on or After a Trastuzumab-Containing Regimen (DESTINY-Gastric04)

Phase 3 Active not recruiting

490 enrolled

Gastrointestinal

Adenocarcinoma, Stomach Neoplasms

NCT06324357 2026-05-26

Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread

Phase 1/2 Recruiting

768 enrolled

BreastGastrointestinal

Adenocarcinoma Of Esophagus, Breast Neoplasms, Colorectal Neoplasms

NCT07069712 2026-05-18

A Study of Novel Agents or Combinations as Perioperative Treatment in Participants With Locally Advanced Resectable Gastroesophageal Adenocarcinoma

Phase 2 Recruiting

100 enrolled

Gastrointestinal

Stomach Neoplasms

NCT06467357 2026-05-14

DESTINY-BTC01

Phase 3 Recruiting

620 enrolled

Gastrointestinal

Biliary Tract Neoplasms

NCT04379596 2026-05-13

DG-03

Phase 2 Recruiting

450 enrolled

Gastrointestinal

Adenocarcinoma, Carcinoma, Esophageal Neoplasms, Stomach Neoplasms

NCT06764875 2026-05-12

A Phase Ⅲ Study of Rilvegostomig in Combination With Fluoropyrimidine and Trastuzumab Deruxtecan as the First-line Treatment for HER2-positive Gastric Cancer

Phase 3 Recruiting

840 enrolled

Gastrointestinal

HER2-positive Gastric Cancer

NCT05993234 2026-05-08

A Study of Trastuzumab DeRuxtecan for Patients With Advanced HER2-pOsitive GaStric or GastroesoPhageal Junction AdEnocarcinoma Who Have Received a PrIor Trastuzumab-based Regimen Accompanied by a Disease RegistrY of Patients Treated With Conventional Therapies (PROSPERITY)

Recruiting

257 enrolled

Gastrointestinal

HER2-positive Advanced Gastric Cancer

NCT04482309 2026-04-09

DPT02

Phase 2 Active not recruiting

477 enrolled 1 FDA

Gastrointestinal

Pancreatic Neoplasms, Colorectal Neoplasms

NCT06731478 2026-03-16

Study of TDXd, Chemotherapy, Pembrolizumab, and Trastuzumab in First-Line Metastatic HER2-Positive Gastric or Gastroesophageal Junction Cancer

Phase 3 Recruiting

726 enrolled

Gastrointestinal

Stomach Neoplasms

NCT04744831 2026-01-14

DESTINY-CRC02

Phase 2 Completed

122 enrolled 21 charts 1 FDA

Gastrointestinal

Colorectal Neoplasms

NCT06846996 2025-07-08

RECOVER

Recruiting

260 enrolled

Gastrointestinal

HER2-positive Gastric Cancer

NCT05824975 2024-11-25

A Study to Evaluate the Safety and Therapeutic Activity of GI-102 As a Single Agent and in Combination with Conventional Anti-cancer Drugs, Pembrolizumab or Trastuzumab Deruxtecan(T-DXd) in Patients with Advanced Solid Tumors (KEYNOTE-G08)

Phase 1/2 Recruiting

358 enrolled

DermatologicGastrointestinalGenitourinarySarcoma

Diabetes Mellitus, Insulin-Dependent, 12, Carcinoma, Renal Cell, Carcinoma, Hepatocellular, Melanoma, Neoplasm Metastasis, Sarcoma, Colorectal Neoplasms

NCT04989816 2024-11-21

DG-06

Phase 2 Completed

95 enrolled 22 charts

Gastrointestinal

Adenocarcinoma, Stomach Neoplasms

NCT03368196 2022-11-03

DS-8201a in Patients With Cancer That Tests Positive for Human Epidermal Growth Factor Receptor 2 (HER2) Protein

Phase 1 Completed

12 enrolled 15 charts

BreastGastrointestinal

Adenocarcinoma, Breast Neoplasms, Neoplasms, Stomach Neoplasms

NCT05091528 2022-08-18

A Safety and Activity Study of SBT6050 in Combination With Other HER2-directed Therapies for HER2-positive Cancers

Phase 1/2 Terminated

2 enrolled 9 charts

BreastGastrointestinalThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Stomach Neoplasms, Colorectal Neoplasms

NCT03329690 2022-03-18

DS-8201a in Human Epidermal Growth Factor Receptor 2 (HER2)-Expressing Gastric Cancer [DESTINY-Gastric01]

Phase 2 Completed

233 enrolled 26 charts 1 FDA

Gastrointestinal

Adenocarcinoma, Gastrointestinal Neoplasms

NCT03384940 2021-10-18

DS-8201a in Human Epidermal Growth Factor Receptor2 (HER2)-Expressing Colorectal Cancer (DESTINY-CRC01)

Phase 2 Completed

86 enrolled 26 charts

Gastrointestinal

Neoplasms, Colorectal Neoplasms

Clinical Trials

CERTIS1

DP-04

Trastuzumab Deruxtecan for Subjects With HER2-Positive Gastric Cancer or Gastro-Esophageal Junction Adenocarcinoma After Progression on or After a Trastuzumab-Containing Regimen (DESTINY-Gastric04)

Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread

A Study of Novel Agents or Combinations as Perioperative Treatment in Participants With Locally Advanced Resectable Gastroesophageal Adenocarcinoma

DESTINY-BTC01

DG-03

A Phase Ⅲ Study of Rilvegostomig in Combination With Fluoropyrimidine and Trastuzumab Deruxtecan as the First-line Treatment for HER2-positive Gastric Cancer

A Study of Trastuzumab DeRuxtecan for Patients With Advanced HER2-pOsitive GaStric or GastroesoPhageal Junction AdEnocarcinoma Who Have Received a PrIor Trastuzumab-based Regimen Accompanied by a Disease RegistrY of Patients Treated With Conventional Therapies (PROSPERITY)

DPT02

Study of TDXd, Chemotherapy, Pembrolizumab, and Trastuzumab in First-Line Metastatic HER2-Positive Gastric or Gastroesophageal Junction Cancer

DESTINY-CRC02

RECOVER

A Study to Evaluate the Safety and Therapeutic Activity of GI-102 As a Single Agent and in Combination with Conventional Anti-cancer Drugs, Pembrolizumab or Trastuzumab Deruxtecan(T-DXd) in Patients with Advanced Solid Tumors (KEYNOTE-G08)

DG-06

DS-8201a in Patients With Cancer That Tests Positive for Human Epidermal Growth Factor Receptor 2 (HER2) Protein

A Safety and Activity Study of SBT6050 in Combination With Other HER2-directed Therapies for HER2-positive Cancers

DS-8201a in Human Epidermal Growth Factor Receptor 2 (HER2)-Expressing Gastric Cancer [DESTINY-Gastric01]

DS-8201a in Human Epidermal Growth Factor Receptor2 (HER2)-Expressing Colorectal Cancer (DESTINY-CRC01)